More than two dozen at­tor­neys gen­er­al push Medicare to cov­er new Alzheimer's treat­ments

Twen­ty-six at­tor­neys gen­er­al on both sides of the aisle called on Medicare on Mon­day to cov­er an­ti­body-based Alzheimer’s treat­ments like Ei­sai and Bio­gen’s Leqem­bi (lecanemab) with­out re­stric­tions and to re­verse a con­tro­ver­sial pol­i­cy that lim­its cov­er­age to pa­tients in clin­i­cal tri­als.

The let­ter, led by Ok­la­homa At­tor­ney Gen­er­al Gen­tner Drum­mond and Min­neso­ta’s Kei­th El­li­son, asked CMS for “full and un­re­strict­ed cov­er­age” of FDA-ap­proved mon­o­clon­al an­ti­bod­ies di­rect­ed against amy­loid for Alzheimer’s treat­ment. The push for change comes from 23 states, the Dis­trict of Co­lum­bia and two US ter­ri­to­ries too.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER